Matinas BioPharma Holdings Management

Management Kriterienprüfungen 3/4

Matinas BioPharma Holdings CEO ist Jerry Jabbour , ernannt in Mar 2016, hat eine Amtszeit von 8.67 Jahren. Die jährliche Gesamtvergütung beträgt $1.60M , bestehend aus 37.4% Gehalt und 62.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.18% der Aktien des Unternehmens, im Wert von $5.53K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.1 Jahre bzw. 6.8 Jahre.

Wichtige Informationen

Jerry Jabbour

Geschäftsführender

US$1.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	37.4%
Amtszeit als Geschäftsführer	8.7yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	6.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.8yrs

Jüngste Management Updates

Recent updates

Here's Why We're Not Too Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Situation

Feb 23

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jerry Jabbour im Vergleich zu den Einnahmen von Matinas BioPharma Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$21m
Jun 30 2024	n/a	n/a	-US$23m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$2m	US$598k	-US$23m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$21m
Dec 31 2022	US$2m	US$575k	-US$21m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$4m	US$545k	-US$24m
Sep 30 2021	n/a	n/a	-US$24m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$3m	US$500k	-US$23m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$1m	US$445k	-US$18m
Sep 30 2019	n/a	n/a	-US$16m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$15m
Dec 31 2018	US$1m	US$366k	-US$15m
Sep 30 2018	n/a	n/a	-US$15m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$16m
Dec 31 2017	US$1m	US$299k	-US$33m

Vergütung im Vergleich zum Markt: JerryDie Gesamtvergütung ($USD1.60M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD646.00K).

Entschädigung vs. Einkommen: JerryDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Jerry Jabbour (50 yo)

8.7yrs

Amtszeit

US$1,599,551

Vergütung

Mr. Jerome D. Jabbour, also known as Jerry, J. D., Co-founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016....

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jerome Jabbour	Co-Founder	8.7yrs	US$1.60m	0.18% $ 5.5k
Keith Kucinski	Chief Financial Officer	5.8yrs	US$626.60k	0.038% $ 1.1k
Frank Calamusa	Executive Director and Head of Manufacturing & Supply Chain	6.1yrs	keine Daten	keine Daten

6.1yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: MTNBDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.1 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jerome Jabbour	Co-Founder	6.7yrs	US$1.60m	0.18% $ 5.5k
Herbert Conrad	Independent Director	11.3yrs	US$141.50k	1.87% $ 56.4k
James Scibetta	Independent Director	11yrs	US$155.00k	0.26% $ 7.8k
David Perlin	Member of Scientific Advisory Board	9.3yrs	keine Daten	keine Daten
Natasha Giordano	Independent Director	4.2yrs	US$145.50k	keine Daten
Matthew Wikler	Independent Director	6.8yrs	US$136.00k	0.12% $ 3.5k
Eric Ende	Independent Chairman of the Board	7.6yrs	US$159.00k	0.057% $ 1.7k
J. Craft	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Kathryn Corzo	Independent Director	3yrs	US$140.00k	keine Daten
Peter Pappas	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Oliver Cornely	Member of Scientific Advisory Board	6.8yrs	keine Daten	keine Daten
Dimitrios Kontoyiannis	Member of Scientific Advisory Board	6.8yrs	keine Daten	keine Daten

6.8yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: MTNBDie Vorstandsmitglieder gelten als erfahren (6.8 Jahre durchschnittliche Amtszeit).

Matinas BioPharma Holdings Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Matinas BioPharma Holdings, Inc. Announces Executive Changes

Insufficient new directors

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 01, 2023

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 14, 2022

Matinas BioPharma Holdings, Inc. Announces Board Changes, Effective October 1, 2022

Insufficient new directors

Recent updates

New major risk - Market cap size

Matinas BioPharma Holdings, Inc. Announces Executive Changes

New minor risk - Share price stability

Matinas BioPharma Holdings, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program

New major risk - Revenue and earnings growth

Matinas BioPharma Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

New minor risk - Shareholder dilution

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

New major risk - Share price stability

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation

Matinas BioPharma Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA

Third quarter 2023 earnings released: US$0.028 loss per share (vs US$0.025 loss in 3Q 2022)

Matinas Biopharma Holdings, Inc. Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Matinas BioPharma Holdings, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Matinas BioPharma Holdings, Inc. Announces Complete Clinical Resolution of a Patient’s Recurrent Hemorrhagic Cystitis Due to Candida krusei Following Treatment with MAT2203

No longer forecast to breakeven

Insufficient new directors

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 01, 2023

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of Mat2203 in the IDSA Journal Clinical Infectious Diseases

Matinas BioPharma Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus revenue estimates fall by 90%

Matinas BioPharma Holdings, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 46%

Forecast to breakeven in 2025

Price target decreased to US$2.75

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Matinas BioPharma Holdings, Inc. Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold, Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 14, 2022

Matinas BioPharma Holdings, Inc. Announces Board Changes, Effective October 1, 2022

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 41,381%

Price target decreased to US$2.75

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Insufficient new directors

Forecast to breakeven in 2024

Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final Cohort of Patients in the Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis

Matinas Biopharma Announces Positive Data in the Ongoing Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold

Consensus forecasts updated

Consensus revenue estimates increase to US$2.48m

Forecast to breakeven in 2025

Consensus revenue estimates increase to US$1.27m

Full year 2020 earnings released: US$0.12 loss per share (vs US$0.13 loss in FY 2019)

Price target decreased to US$3.08

Here's Why We're Not Too Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Situation

Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®

Price target raised to US$3.75

Matinas BioPharma Holdings, Inc. Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001

New 90-day high: US$1.47

Matinas Biopharma Holdings, Inc. Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas LNC Platform Delivery Technology

Matinas BioPharma Holdings, Inc. Appoints Hui Liu as Chief Technology Officer

New 90-day high: US$0.90

Matinas BioPharma Holdings, Inc. Awards Up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients

Analysts increase revenue estimates to US$1.37m